EPAS1 and metabolic dysfunction-associated steatohepatitis: Taken together, our data strongly suggest that the HIF2α/CD36 pathway could have a pathogenic role in the phase of hepatosteatosis, but further investigation is needed for understanding in depth its impact on NASH progression.